<DOC>
	<DOCNO>NCT01818323</DOCNO>
	<brief_summary>The overall goal study investigate safety T4 immunotherapy administer treat loco-regional disease Squamous Cell Cancer Head Neck ( SCCHN ) suitable conventional active therapy . The investigator propose conduct open-labelled , non-randomized , dose-escalation phase I trial autologous T4+ T-cells administer patient SCCHN . T-cells engineer express second generation chimeric antigen receptor ( CAR ) name T1E28z . Engineered T-cells inject directly tumour site . Patients lymphodepleted . A classical 3+3 design employ , dose escalation 10^7 10^9 transduced T4+ T-cells , dependent upon toxicity monitoring . It anticipate 30 patient enrol course study .</brief_summary>
	<brief_title>Phase I Trial : T4 Immunotherapy Head Neck Cancer</brief_title>
	<detailed_description>Further information provide van Schalkwyk MC , Papa SE , Jeannon JP , Guerrero Urbano T , Spicer JF , Maher J . Design phase I clinical trial evaluate intratumoral delivery ErbB-targeted chimeric antigen receptor T-cells locally advance recurrent head neck cancer . Hum Gene Ther Clin Dev . 2013 Sep ; 24 ( 3 ) :134-42. doi : 10.1089/humc.2013.144 . PubMed ID : 24099518</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>1 . Histologically and/ cytologically confirm SCCHN . 2 . 18 year old . 3 . Locally advanced and/ recurrent head neck cancer without metastatic disease ( exclude brain metastasis ) standard therapy remain suitable . 4 . Regarding previous treatment , patient may receive prior systemic therapy , include platinum chemotherapy , least one month earlier . In presence metastatic disease , recent shortcourse palliative radiotherapy nontarget site ( ) allow . 5 . Those refuse palliative treatment may eligible participation . However , reason opt palliative treatment must explore thoroughly . 6 . At least one locoregional target lesion measurable RECIST v1.1 criterion CT MRI scan within four week enrolment , amenable intratumoral injection . 7 . Eastern Cooperative Oncology Performance Status 02 . 8 . Normal cardiac function assess electrocardiography either echocardiography ( ECHO ) , multigated acquisition ( MUGA ) scanning . Left ventricular ejection fraction must &gt; 50 % . Assessment must take place within four week enrolment . 9 . Haematology result within seven day enrolment : neutrophil &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L , haemoglobin &gt; 9g/dl , INR &lt; 1.5 . 10 . Biochemistry result within seven day enrolment : • serum creatinine &lt; 1.5 upper limit normal • bilirubin &lt; 1.25 time normal ; • ALT/ AST &lt; 2.5 time upper limit normal ( &lt; 5 time upper limit normal liver metastasis present ) 11 . Female patient must postmenopausal ( 12 month amenorrhea ) , surgically sterile must agree use physical method contraception . Oral injectable contraceptive agent sole method contraception . Women childbearing potential ( WOCB ) receive cyclophosphamide must adhere contraceptive requirement trial 3 month last dose cyclophosphamide . Male patient , even sterilize , must agree use barrier method contraception . Male subject must also commit use barrier method contraception least 3 month end study treatment . 12 . Written inform consent prior registration . 13 . Eligible NHS care UK . 1 . The presence imminent occurrence airway obstruction , unless tracheostomy place . 2 . The presence imminent occurrence tumourmediated infiltration major blood vessel . 3 . Positive history HIV1 , HIV2 , HTLV1 , HTLV2 , Hepatitis B , Hepatitis C syphilis infection . 4 . Prior splenectomy . 5 . Clinically active autoimmune disease . Subclinical quiescent autoimmune disease exclude participation . 6 . Treatment precede week systemic corticosteroid ( &gt; 20mg prednisolone/ day ) , systemic immunomodulatory agent , radiotherapy , chemotherapy investigational medicinal product . 7 . Concurrent use anticoagulant therapy permissible . 8 . The presence major comorbidity likely impair ability undergo trial therapy , recent myocardial infarction , congestive cardiac failure uncontrolled hypertension . 9 . The presence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule . 10 . Cyclophosphamide allergy ( Cohort 6 ) . 11 . Pregnancy . 12 . Breastfeeding . 13 . Prior T4 immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chimeric antigen receptor</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Phase I trial</keyword>
	<keyword>Maximum tolerate dose</keyword>
</DOC>